Bayer's Langreo Plant in Spain to Become First Fully Decarbonized Pharma Site, Cutting 6,500 Tonnes CO2

Bayer is pushing its Langreo, Spain site to become the first fully decarbonized pharmaceutical production plant in the country. The company invested EUR 17 million in a new energy system that is now in test operation and should enter regular service before the end of 2026. Bayer says the project will avoid more than 6,500 tonnes of carbon dioxide per year and bring process emissions from the Aspirin active-ingredient plant close to zero. The decarbonization push is part of a wider corporate reshuffle that includes selling the cancer drug Stivarga to Grünenthal for up to EUR 375 million and issuing EUR 2 billion in hybrid bonds. The Langreo project also earned recognition from utility Iberdrola's Convive awards, though the emission reduction figure has not been independently verified. For anyone tracking low-carbon industrial projects, the site is a useful example of how legacy pharma manufacturing can cut process emissions. The key missing detail is the specific energy technology being deployed, which will determine whether the plant can really run carbon-free around the clock.